Lexeo Therapeutics (LXEO) Insider Kirstine Buys 35,000 Shares

On June 25, 2026, Agger Mette Kirstine purchased 35,000 shares of Lexeo Therapeutics, Inc. (NasdaqGM: LXEO). This insider transaction is notable as it reflects confidence in the company's prospects. The shares were acquired at no cost under the transaction code 'A'.

Insider Buying and Selling at Lexeo Therapeutics, Inc.

Several insiders, including Agger Mette Kirstine, Timothy Van Hauwermeiren, Steven Altschuler, Brenda Cooperstone, Tolga Tanguler, and Reinaldo Diaz, each bought 35,000 shares of Lexeo Therapeutics on June 25, 2026. These acquisitions were not part of a pre-planned trading program.

Other Institutional Activity in Lexeo Therapeutics

In recent institutional activity, Paradigm Biocapital Advisors LP increased its holdings by 1,420,936 shares, bringing its total to 6,184,134 shares valued at approximately $35.50 million, marking a 29.8% increase. BlackRock, Inc. added 203,308 shares, ending with 5,110,871 shares worth about $29.34 million, a 4.1% increase. Affinity Asset Advisors, LLC grew its stake by 1,850,211 shares, resulting in a 57.8% increase, with a total of 5,050,211 shares valued at $28.99 million. Janus Henderson Group PLC, however, reduced its position by 533,206 shares, a 9.7% decrease, holding 4,976,429 shares valued at $28.51 million.

Lexeo Therapeutics, Inc. Stock Up 14.5%

Shares of Lexeo Therapeutics traded near $4.75 on Tuesday. The company has a market capitalization of $372.98 million. Although not currently profitable, it operates with a forward P/E of -3.82 and a beta of 1.389, indicating higher volatility compared to the market. The stock's 52-week range is between $3.60 and $10.99, with a 50-day moving average of $5.27 and a 200-day moving average of $7.14. Lexeo maintains a strong financial position with a current ratio of 14.16 and a quick ratio of 13.61, alongside a debt-to-equity ratio of 3.18.

Analysts Set New Price Targets

On June 25, 2026, JP Morgan maintained its buy rating for Lexeo Therapeutics with a price target of $9.00. Chardan Capital also maintained its buy rating with a target of $17.00 as of May 11, 2026. Overall, the stock has a strong buy consensus with a mean price target of $20.60 from 10 analyst opinions.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc., based in New York, is a clinical-stage biotechnology company focused on developing genetic medicines for hereditary and acquired diseases with high unmet needs. Led by CEO R. Nolan Townsend, the company is working on several gene therapy candidates, including those targeting Friedreich ataxia cardiomyopathy and Alzheimer's disease. Founded in 2017, Lexeo aims to address critical healthcare challenges through innovative therapies.

Bottom Line

The insider purchase by Agger Mette Kirstine and others at Lexeo Therapeutics is a signal of internal confidence as the company advances its genetic medicine pipeline. Investors often track such insider activity for insights into the company's future prospects. Remember, these insider transactions are disclosed after they occur, offering a historical view of ownership changes.